on NANOBIOTIX (EPA:NANO)
NANOBIOTIX: Reclassification and New Patent for JNJ-1900 (NBTXR3)
Nanobiotix announces two key advancements regarding its product candidate JNJ-1900 (NBTXR3). This radioenhancer has been reclassified as a drug by European health authorities, aligning its regulatory status with that of the United States and other major markets.
This reclassification, based on recent data on its mechanism of action, facilitates global regulatory harmonization and supports future international strategies. At the same time, Nanobiotix has filed an application for a new composition patent, thereby strengthening the product's intellectual property rights.
JNJ-1900 (NBTXR3) continues its global clinical development, including a Phase 3 trial in head and neck cancer. The company is committed to advancing the product for patients awaiting new therapeutic options.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news